153 related articles for article (PubMed ID: 28370948)
1. Cost-effectiveness of a new urinary biomarker-based risk score compared to standard of care in prostate cancer diagnostics - a decision analytical model.
Dijkstra S; Govers TM; Hendriks RJ; Schalken JA; Van Criekinge W; Van Neste L; Grutters JPC; Sedelaar JPM; van Oort IM
BJU Int; 2017 Nov; 120(5):659-665. PubMed ID: 28370948
[TBL] [Abstract][Full Text] [Related]
2. Cost-Effectiveness of Urinary Biomarker Panel in Prostate Cancer Risk Assessment.
Govers TM; Caba L; Resnick MJ
J Urol; 2018 Dec; 200(6):1221-1226. PubMed ID: 30012363
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of SelectMDx for prostate cancer in four European countries: a comparative modeling study.
Govers TM; Hessels D; Vlaeminck-Guillem V; Schmitz-Dräger BJ; Stief CG; Martinez-Ballesteros C; Ferro M; Borque-Fernando A; Rubio-Briones J; Sedelaar JPM; van Criekinge W; Schalken JA
Prostate Cancer Prostatic Dis; 2019 Mar; 22(1):101-109. PubMed ID: 30127462
[TBL] [Abstract][Full Text] [Related]
4. Incorporating Biomarkers into the Primary Prostate Biopsy Setting: A Cost-Effectiveness Analysis.
Sathianathen NJ; Kuntz KM; Alarid-Escudero F; Lawrentschuk NL; Bolton DM; Murphy DG; Weight CJ; Konety BR
J Urol; 2018 Dec; 200(6):1215-1220. PubMed ID: 29906434
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of magnetic resonance (MR) imaging and MR-guided targeted biopsy versus systematic transrectal ultrasound-guided biopsy in diagnosing prostate cancer: a modelling study from a health care perspective.
de Rooij M; Crienen S; Witjes JA; Barentsz JO; Rovers MM; Grutters JP
Eur Urol; 2014 Sep; 66(3):430-6. PubMed ID: 24377803
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of an urinary biomarker panel in combination with MRI for prostate cancer diagnosis.
Govers TM; Resnick MJ; Rastinehad AR; Caba L; Groskopf J; van Criekinge W
World J Urol; 2023 Jun; 41(6):1527-1532. PubMed ID: 37133554
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of percent free PSA for prostate cancer detection in men with a total PSA of 4-10 ng/ml.
Bermúdez-Tamayo C; Martín Martín JJ; González Mdel P; Pérez Romero C
Urol Int; 2007; 79(4):336-44. PubMed ID: 18025853
[TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness of a Biopsy-Based 8-Protein Prostate Cancer Prognostic Assay to Optimize Treatment Decision Making in Gleason 3 + 3 and 3 + 4 Early Stage Prostate Cancer.
Roth JA; Ramsey SD; Carlson JJ
Oncologist; 2015 Dec; 20(12):1355-64. PubMed ID: 26482553
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of Prostate Health Index for prostate cancer detection.
Nichol MB; Wu J; Huang J; Denham D; Frencher SK; Jacobsen SJ
BJU Int; 2012 Aug; 110(3):353-62. PubMed ID: 22077934
[TBL] [Abstract][Full Text] [Related]
10. A urinary biomarker-based risk score correlates with multiparametric MRI for prostate cancer detection.
Hendriks RJ; van der Leest MMG; Dijkstra S; Barentsz JO; Van Criekinge W; Hulsbergen-van de Kaa CA; Schalken JA; Mulders PFA; van Oort IM
Prostate; 2017 Oct; 77(14):1401-1407. PubMed ID: 28853167
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of MR Imaging-guided Strategies for Detection of Prostate Cancer in Biopsy-Naive Men.
Pahwa S; Schiltz NK; Ponsky LE; Lu Z; Griswold MA; Gulani V
Radiology; 2017 Oct; 285(1):157-166. PubMed ID: 28514203
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness Analysis of Active Surveillance Strategies for Men with Low-risk Prostate Cancer.
Sathianathen NJ; Konety BR; Alarid-Escudero F; Lawrentschuk N; Bolton DM; Kuntz KM
Eur Urol; 2019 Jun; 75(6):910-917. PubMed ID: 30425010
[TBL] [Abstract][Full Text] [Related]
13. Clinically significant Prostate Cancer diagnosed using a urinary molecular biomarker-based risk score: two case reports.
Minnee P; Hessels D; Schalken JA; Van Criekinge W
BMC Urol; 2019 Nov; 19(1):124. PubMed ID: 31783839
[TBL] [Abstract][Full Text] [Related]
14. Clinical use of the mRNA urinary biomarker SelectMDx test for prostate cancer.
Visser WCH; de Jong H; Steyaert S; Melchers WJG; Mulders PFA; Schalken JA
Prostate Cancer Prostatic Dis; 2022 Sep; 25(3):583-589. PubMed ID: 35810263
[TBL] [Abstract][Full Text] [Related]
15. Cost-Effectiveness of Annual Prostate MRI and Potential MRI-Guided Biopsy After Prostate-Specific Antigen Test Results.
Yun H; Kim J; Gandhe A; Nelson B; Hu JC; Gulani V; Margolis D; Schackman BR; Jalali A
JAMA Netw Open; 2023 Nov; 6(11):e2344856. PubMed ID: 38019516
[TBL] [Abstract][Full Text] [Related]
16. The cost-effectiveness of prostate health index for prostate cancer detection in Chinese men.
Teoh JY; Leung CH; Wang MH; Chiu PK; Yee CH; Ng CF; Wong MC
Prostate Cancer Prostatic Dis; 2020 Dec; 23(4):615-621. PubMed ID: 32606435
[TBL] [Abstract][Full Text] [Related]
17. Economic Analysis of Prostate-Specific Antigen Screening and Selective Treatment Strategies.
Roth JA; Gulati R; Gore JL; Cooperberg MR; Etzioni R
JAMA Oncol; 2016 Jul; 2(7):890-8. PubMed ID: 27010943
[TBL] [Abstract][Full Text] [Related]
18. The prostate: decreasing cost-effectiveness of biopsy with advancing age.
Gottlieb RH; Mooney C; Mushlin AI; Rubens DJ; Fultz PJ
Invest Radiol; 1996 Feb; 31(2):84-90. PubMed ID: 8750443
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis of multiparametric MRI with increased active surveillance for low-risk prostate cancer in Australia.
Gordon LG; James R; Tuffaha HW; Lowe A; Yaxley J
J Magn Reson Imaging; 2017 May; 45(5):1304-1315. PubMed ID: 27726240
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of standard vs intensive antibiotic regimens for transrectal ultrasonography (TRUS)-guided prostate biopsy prophylaxis.
Adibi M; Pearle MS; Lotan Y
BJU Int; 2012 Jul; 110(2 Pt 2):E86-91. PubMed ID: 22115356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
